Akero Therapeutics Past Earnings Performance
Past criteria checks 0/6
Akero Therapeutics's earnings have been declining at an average annual rate of -24.9%, while the Biotechs industry saw earnings growing at 7.7% annually.
Key information
-24.9%
Earnings growth rate
8.7%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | n/a |
| Return on equity | -32.1% |
| Net Margin | n/a |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How Akero Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 0 | -237 | 38 | 232 |
| 30 Jun 24 | 0 | -204 | 36 | 198 |
| 31 Mar 24 | 0 | -179 | 33 | 171 |
| 31 Dec 23 | 0 | -152 | 31 | 142 |
| 30 Sep 23 | 0 | -120 | 30 | 107 |
| 30 Jun 23 | 0 | -116 | 33 | 93 |
| 31 Mar 23 | 0 | -112 | 31 | 87 |
| 31 Dec 22 | 0 | -112 | 30 | 85 |
| 30 Sep 22 | 0 | -121 | 28 | 95 |
| 30 Jun 22 | 0 | -110 | 21 | 89 |
| 31 Mar 22 | 0 | -112 | 20 | 92 |
| 31 Dec 21 | 0 | -101 | 19 | 82 |
| 30 Sep 21 | 0 | -98 | 18 | 80 |
| 30 Jun 21 | 0 | -95 | 18 | 78 |
| 31 Mar 21 | 0 | -82 | 16 | 67 |
| 31 Dec 20 | 0 | -79 | 15 | 65 |
| 30 Sep 20 | 0 | -65 | 14 | 52 |
| 30 Jun 20 | 0 | -59 | 13 | 49 |
| 31 Mar 20 | 0 | -50 | 11 | 42 |
| 31 Dec 19 | 0 | -44 | 9 | 37 |
| 30 Sep 19 | 0 | -90 | 7 | 26 |
| 30 Jun 19 | 0 | -86 | 5 | 13 |
| 31 Mar 19 | 0 | -87 | 3 | 16 |
| 31 Dec 18 | 0 | -82 | 2 | 12 |
| 30 Sep 18 | 0 | -22 | 1 | 11 |
Quality Earnings: 0K4 is currently unprofitable.
Growing Profit Margin: 0K4 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 0K4 is unprofitable, and losses have increased over the past 5 years at a rate of 24.9% per year.
Accelerating Growth: Unable to compare 0K4's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 0K4 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.2%).
Return on Equity
High ROE: 0K4 has a negative Return on Equity (-32.13%), as it is currently unprofitable.